What’s the best way to address high drug prices? That’s a tough question, but one angle that gets less public attention is the high cost of early-stage development.
What’s the best way to address high drug prices? That’s a tough question, but one angle that gets less public attention is the high cost of early-stage development. FDA Commissioner Scott Gottlieb recently outlined steps the agency is taking to streamline the early development process where, he says, inflation is rising the fastest. -KT
